ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Ocular Therapeutix (OCUL) pipeline and stated timing

Name in SEC filings: OCULAR THERAPEUTIX, INC

Pipeline at a glance

ProgramEventStageStated timingFiling
AXPAXLI (OTX-TKI)/data readoutStage not statedfourth quarter of 202610-Q ·
AXPAXLI (OTX-TKI) submission—fourth quarter of 202610-Q ·

Source: ORION, orionbiotechai.com/company/OCUL, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/OCUL

Nearest upcoming stated timing: AXPAXLI (OTX-TKI) · Topline/data readout · fourth quarter of 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

AXPAXLI (OTX-TKI)

Matched

Topline/data readoutfourth quarter of 2026

Stage: Not stated

Public float: $1,604,700,000 · as of · SEC filing

we plan to conduct an interim safety analysis of the SOL-R trial in the fourth quarter of 2026 to provide Week 52 safety data on subjects dosed with AXPAXLI in the trial in support of our NDA for AXPAXLI for the treatment of wet AMD.

10-Q · Filed · Last checked

Source details

Accession 0001104659-26-089450

Alert me · Calendar: same stage and window-end month (2026-12)

AXPAXLI (OTX-TKI)

Matched

NDA/BLA submissionfourth quarter of 2026

Stage: —

Public float: $1,604,700,000 · as of · SEC filing

we anticipate submitting a new drug application, or NDA, to the FDA for marketing approval of AXPAXLI for the treatment of wet AMD during the fourth quarter of 2026.

10-Q · Filed · Last checked

Source details

Accession 0001104659-26-089450

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
AXPAXLI (OTX-TKI)Clinical resultsfourth quarter of 2026
“we plan to conduct an interim safety analysis of the SOL-R trial in the fourth quarter of 2026 to provide Week 52 safety data on subjects dosed with AXPAXLI in the trial in support of our NDA for AXPAXLI for the treatment of wet AMD.”

Filed · 10-Q

Still within period

As of Oct 19, 2026

AXPAXLI (OTX-TKI)Submissionfourth quarter of 2026
“we anticipate submitting a new drug application, or NDA, to the FDA for marketing approval of AXPAXLI for the treatment of wet AMD during the fourth quarter of 2026.”

Filed · 10-Q

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch OCUL

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for OCUL. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See OCUL in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.A New Drug Application (NDA) or Biologics License Application (BLA) asks the FDA to approve a drug or biologic for sale.